α-thalassemia is one of the most prevalent genetic disorders in the Eastern hemisphere. In the past, successful forms of therapy have been extremely difficult to identify. However, with recent developments in gene therapy many forms of treatment have been discovered. These forms of treatment are quite vital to the survival of many individuals suffering from thalassemia, yet lack of FDA approval has thwarted them from being accessible to the modern medical field and practices. Sign below if you would like to have your voice heard.